Proteomics in Neurodegeneration

Proteomics in Neurodegeneration

bfe67bb53c3c532ef4237fa3323691ae27404769

Proteomics — the large-scale study of proteins, their structures, functions, and interactions — has become an indispensable technology in neurodegenerative disease research. By profiling thousands of proteins simultaneously in brain tissue, cerebrospinal fluid (CSF), and blood, proteomic approaches have identified novel disease biomarkers, revealed unexpected pathological pathways, and uncovered potential therapeutic targets for [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [FTD](/diseases/ftd), and other neurodegenerative conditions[@yarbro2025][@johnson2020].

The proteomic revolution in neurodegeneration has been driven by advances in mass spectrometry (MS) sensitivity and throughput, affinity-based multiplexed platforms, and emerging single-cell and spatial proteomic techniques that provide unprecedented resolution of cellular heterogeneity within the diseased brain[@bader2020].

Mass Spectrometry-Based Proteomics

Proteomics in Neurodegeneration

bfe67bb53c3c532ef4237fa3323691ae27404769

Proteomics — the large-scale study of proteins, their structures, functions, and interactions — has become an indispensable technology in neurodegenerative disease research. By profiling thousands of proteins simultaneously in brain tissue, cerebrospinal fluid (CSF), and blood, proteomic approaches have identified novel disease biomarkers, revealed unexpected pathological pathways, and uncovered potential therapeutic targets for [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [FTD](/diseases/ftd), and other neurodegenerative conditions[@yarbro2025][@johnson2020].

The proteomic revolution in neurodegeneration has been driven by advances in mass spectrometry (MS) sensitivity and throughput, affinity-based multiplexed platforms, and emerging single-cell and spatial proteomic techniques that provide unprecedented resolution of cellular heterogeneity within the diseased brain[@bader2020].

Mass Spectrometry-Based Proteomics

Shotgun Proteomics (Bottom-Up)

The most widely used approach in neurodegeneration research is bottom-up (shotgun) proteomics, where proteins are enzymatically digested into peptides, separated by liquid chromatography, and analyzed by tandem mass spectrometry (LC-MS/MS). Key methodological advances include:[@satpathy2020]

• Tandem Mass Tag (TMT) labeling: Enables multiplexed quantitative comparison of up to 18 samples simultaneously, widely used in multi-cohort brain tissue analyses[@yarbro2025]
• Data-Independent Acquisition (DIA/SWATH-MS): Provides comprehensive and reproducible quantification across large sample sets without preselection[@johnson2020]
• Data-Dependent Acquisition (DDA): Traditional discovery-based approach for identifying novel proteins

Top-Down Proteomics

Top-down approaches analyze intact proteins without enzymatic digestion, preserving information about post-translational modifications (PTMs), protein isoforms, and truncation products. This is particularly valuable for studying [tau](/proteins/tau-protein) proteoforms, [amyloid-beta](/proteins/amyloid-beta) peptide variants, and [alpha-synuclein](/proteins/alpha-synuclein) modifications in neurodegenerative diseases[@sato2018].

Targeted Proteomics (SRM/PRM)

Selected reaction monitoring (SRM) and parallel reaction monitoring (PRM) enable precise quantification of predefined protein panels with high sensitivity and reproducibility — ideal for clinical biomarker validation.

Affinity-Based Proteomic Platforms

SomaScan (Aptamer-Based)

bfe67bb53c3c532ef4237fa3323691ae27404769

Olink (Proximity Extension Assay)

The Olink platform uses antibody-based proximity extension assays (PEA) to measure up to 3,000 proteins simultaneously with high sensitivity and specificity. Olink has been deployed in large biobank studies to identify causal protein-disease relationships through Mendelian randomization approaches[@bader2020].

Key Proteomic Discoveries in Neurodegeneration

Alzheimer's Disease Brain Proteome

Multi-cohort proteomic analyses of AD brain tissue have identified a consensus set of ~866 proteins that are consistently altered in Alzheimer's Disease[@yarbro2025]. Key findings include:

• Upregulated proteins: Midkine (MDK), pleiotrophin (PTN), netrin-1 (NTN1), SPARC-related modular calcium-binding protein 1 (SMOC1), and glycoprotein NMB (GPNMB)
• Downregulated proteins: Neuronal pentraxin-2 (NPTX2), neuritin (NRN1), and VGF nerve growth factor inducible
• RNA splicing defects: U1 small nuclear ribonucleoprotein (U1 snRNP) components are consistently dysregulated, suggesting widespread splicing defects in AD
• Pan-neurodegeneration markers: [NFL](/proteins/neurofilament-light-chain-nfl) as a marker of axonal damage, [GFAP](/proteins/gfap-alzheimers) as an astrocytic activation marker elevated in early AD[@johnson2020]

CSF Proteomics

CSF proteomic panels have improved diagnostic accuracy for differentiating AD from other neurodegenerative diseases and for staging disease progression. Novel CSF biomarkers identified through proteomics include SMOC1, YWHAG, and NPTX2[@sato2018].

Emerging Technologies

Single-Cell Proteomics

Single-cell proteomics enables protein quantification in individual cells, revealing cell-type-specific proteomic changes in neurodegeneration. Techniques like SCoPE2 and plexDIA can now quantify >1,000 proteins per single cell, enabling characterization of [disease-associated microglia](/cell-types/microglia) and vulnerable [neurons](/cell-types/neurons) at unprecedented resolution[@kerenshaul2017].

Spatial Proteomics

Spatial proteomic methods — including MALDI-MSI, CODEX, and MIBI-TOF — map protein distributions within intact brain tissue sections, revealing the spatial relationship between protein aggregates, cellular responses, and tissue pathology. These approaches complement [spatial transcriptomics](/technologies/spatial-transcriptomics) by providing direct protein-level information.

Amyloidome Profiling

The "amyloidome" refers to the full complement of proteins that co-aggregate with amyloid deposits in the brain. Proteomic analysis of isolated amyloid plaques and [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles) has revealed hundreds of co-aggregating proteins, many with unexpected roles in disease pathogenesis[@yarbro2025].

Global Neurodegeneration Proteomics Consortium (GNPC)

The GNPC, a public-private partnership, has established one of the world's largest harmonized proteomic datasets for neurodegeneration. Consortium analyses identified both disease-specific and transdiagnostic signatures across [Alzheimer's](/diseases/alzheimers-disease), [Parkinson's](/diseases/parkinsons-disease), [ALS](/diseases/als), and [FTD](/diseases/ftd)[@johnson2020].

Key translational implications include:

• Proteomic subtype discovery for patient stratification in clinical trials
• Cross-fluid biomarker panels linking plasma and CSF protein states
• Candidate target prioritization for mechanism-specific therapeutics

Key Publications

Cross-Links

• [CSF Biomarkers in Neurodegeneration](/biomarkers/csf-biomarkers-neurodegenerative-disease)
• [Blood-Based Biomarkers](/biomarkers/blood-based-biomarkers-neurodegeneration)
• [Single-Cell Genomics](/technologies/single-cell-genomics)
• [Spatial Transcriptomics](/technologies/spatial-transcriptomics)
• [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)